Steroid hormones such as 17b-estradiol (E2) are critical to diverse cellular processes including tumorigenesis. A number of cofactors such as nuclear receptor corepressor (NCoR), CREB-binding protein (CBP), and steroid receptor coactivator 1 (SRC-1) interact with estrogen receptors (ERs) to regulate transcriptional repression or activation of target genes. Estrogen signaling in non-reproductive tract tissues such as skin is less well characterized and the effectiveness of anti-estrogen therapy for cancer arising from these tissues is unknown. We show that tamoxifen (TAM) treatment inhibited cell cycle progression and proliferation of human cancer lines derived from stratified squamous epithelium squamous cell carcinoma (SCC). E2 had no effect on proliferation of these lines despite low levels of ERa expression. The E2 treatment promoted displacement of the NCoR from ERa and recruitment of CBP to the receptor. SRC-1 expression was not detected in these SCC lines; however, transient transfection of SRC-1, CBP, or both coactivators enhanced transactivation of an estrogen responsive promoter in cancer cells treated with E2 or TAM. In stable clones expressing SRC-1, the coactivator was recruited to ERa along with CBP in E2 but not in TAM-treated cells. SRC-1 expression restored the E2-mediated proliferative response to human SCC lines. This increased proliferation correlated with increased extracellular signal regulated kinase 1 (ERK1) expression. SRC-1 and CBP were recruited to the proximal ERK1 promoter region in E2 but not in TAMtreated cells. We concluded that SRC-1 was a key molecular determinant of estrogen-mediated proliferation in human SCC lines.
Introduction
Steroid hormones such as 17b-estradiol (E2) are critical to diverse cellular processes including development, reproduction, and tumorigenesis (Kim et al. 2001) . The E2 functions through its receptors ERa and ERb (Couse & Korach 1999) . ERs belong to the superfamily of nuclear hormone receptors that are ligand-dependent transcription factors (Mangelsdorf et al. 1995) . The ERa binds to estrogen response elements in the promoters of responsive genes. A number of cofactors interact with ERa to regulate transcriptional repression or activation. Among the repressive cofactors is nuclear receptor corepressor (NCoR), which interacts with ERa in the presence of the anti-estrogen 4-hydroxytamoxifen (TAM; Huang et al. 2002) . Chimeric NCoR-ERa proteins have been shown to silence basal transcription of ERa responsive genes (Chien et al. 1999) . Dissociation of corepressors from ERa correlates with estrogen-dependent responses (Carroll et al. 2003) . Loss of corepressor interaction with ERa leads to recruitment of coactivators, which serve to recruit other cofactors, acetylate nucleosomal histones, and bind basal transcriptional machinery (Ratajczak 2001) . Histone acetylation results in more open chromatin structure and increased transcriptional activity (Kornberg & Lorch 1999) . Interactions between activated ERa bound to DNA and coactivators such as steroid receptor coactivator 1 (SRC-1) and CREB-binding protein (CBP) regulate the transcription of estrogen target genes (Robyr et al. 2000) .
SRC-1 functions primarily as coactivator for nuclear receptors and binds directly to liganded ERa through helical LXXLL motifs (Needham et al. 2000) . The SRC-1 contributes to transcriptional activation by interacting with other coactivators such as CBP (Smith et al. 1996 , Sheppard et al. 2001 . Coactivators such as SRC-1 and CBP possess histone acetyltransferase activity, which can disrupt nucleosomal structure leading to transcriptional activation (Spencer et al. 1997) . Disruption of the SRC-1 gene in mice leads to partial hormone resistance in target organs such as uterus, prostate, testis, and mammary gland (Xu et al. 1998) .
The estrogen response in non-reproductive tract tissues such as skin and other stratified squamous epithelia is less well characterized. Estrogen has clinically important functions in epidermis, hair follicles, and secretory glands (for review see Thornton 2002) . The E2 treatment increased proliferation and thickness of epidermis in wild-type but not ERa in null mutant mice (Moverare et al. 2002) ; E2 enhanced proliferation of human keratinocytes in vitro by inducing cyclin D2 expression (Kanda & Watanabe 2004) . In human clinical trials, E2 treatment increased epidermal thickness and reduced the prevalence of histologic features associated with aging (Fuchs et al. 2003) . E2 increased expression of type I collagen, tropoelastin, fibrillin-1, and elastic fibers in aged skin in vivo (Son et al. 2005) . These studies indicate that ERa signaling can increase keratinocyte proliferation and extracellular matrix production in human skin cells in vivo and in vitro.
Conversely, treatment with antiestrogens, such as TAM, inhibits proliferation of estrogen-responsive cancer cells. Proliferation of breast and ovarian cancer cell lines was inhibited by TAM (Lindner & Borden 1997 , Cariou et al. 2000 . High doses of antiestrogens have also been shown to inhibit proliferation and induce apoptosis in an ERa negative ovarian carcinoma cell line (Ercoli et al. 1998) . However, the mechanism by which TAM inhibits proliferation of cancer cells from non-reproductive tissues such as stratified squamous epithelium is not well characterized. Furthermore, ERa expression is reportedly low in stratified squamous epithelia from different anatomic sites (Ojanotko-Harri et al. 1992) . Coactivator expression and interaction with ERa in regulating cancer cell proliferation from this tissue are largely unknown. We demonstrate that TAM but not E2 regulates cell cycle progression and proliferation of human squamous cell carcinoma (SCC) lines. We show that the SRC-1 coactivator protein is a key molecular determinant of this differential response to ERa signaling.
Materials and Methods

Cell culture and stable transfection
The human SCC lines used in this study were purchased from the American Type Culture Collection. Cells were cultured in Dulbecco's modified Eagle medium without phenol red, 10% charcoal-stripped fetal bovine serum, 40 mg/ml gentamicin at 37 8C in a humidified atmosphere of 5% CO 2 . SCC4, SCC9, or SCC25 cells were transfected with 5 mg human SRC-1 expression vector (kindly provided by Dr Ronald Evans) or neomycin-resistance plasmid alone using Lipofectamine reagent according to the manufacturer's recommendations (Invitrogen). Cells were selected in 400 mg/ml G418 for 14 days. Resistant clones were picked for expansion and characterization. The human breast cancer cell lines MCF7 (ERa positive) and MDA-MB-231 (ERa negative) were used as well characterized controls for ERa expression.
Cell proliferation and BrdU incorporation analysis
Triplicate cultures of 5!10 4 parental SCC lines, SRC-1, or vector control clones were plated into six-well plates and treated with 10-1000 nM E2 or 4-hydroxytamoxifen for up to 6 days. The control cultures were treated with 0 . 1% ethanol vehicle for the same time period and they were trypsinized and counted at 2-day intervals using a hemacytometer. For bromodeoxyuridine (BrdU) incorporation analysis, cells were treated with ligands or vehicle for 1 day followed by 1-h incubation in 10 mM BrdU. After washing in PBS, cells were fixed in 70% ethanol, 50 mM glycine (pH 2) for 30 min at K20 8C. After extensive washing in PBS, cells were incubated with mouse anti-BrdU primary antibody at 37 8C for 30 min (Roche Molecular Biochemicals). After washing in PBS, cells were incubated with anti-mouse IgG secondary antibody conjugated to fluorescein at 37 8C for 30 min. Following extensive washing in PBS, BrdU-positive cells were visualized by fluorescence microscopy. The number of positive cells was expressed as a percentage of total cells counted in ten randomly selected high power fields.
Reverse transcription-PCR
RNA was extracted from SCC and breast cancer cell lines using a commercially available kit (Qiagen) and reverse transcribed using SuperScript II reverse transcriptase according to the manufacturer's instructions (Invitrogen). cDNA was amplified using ERa specific primers (5 0 -CCACCAACCAGTGCACCATT-3 0 and 5 0 -GGTCTT TTCGTATCCCACCTTTC-3 0 ) in 20 mM Tris-HCl (pH 8 . 3), 1 . 5 mM MgCl 2 , 63 mM KCl, 0 . 05% Tween 20, 1 mM EGTA, 50 mM of each dNTP, and 2 . 5 U Taq DNA polymerase (Roche Molecular Biochemicals). Amplification with b-actin cDNA using primers 5 0 -ACAGGAAGT CCCTTGCCATC-3 0 and 5 0 -ACTGGTCTCAAGTCAG TGTACAGG-3 0 as the internal control was carried out by real-time PCR (iCycler, BioRad) using cycle parameters 94 8C for 25 s, 55 8C for 1 min, and 72 8C for 1 min.
Immunoprecipitation and western blot
Cultures of ligand or vehicle-treated SCC lines and clones were lysed in 50 mM HEPES (pH 7 . 5), 150 mM NaCl, 1 mM EDTA, 2 . 5 mM EGTA, 1 mM dithiothreitol, 1% Nonidet P-40, 10% glycerol, and protease inhibitors for 30 min at 4 8C. Lysates were centrifuged at 10 000 g for 10 min and anti-human primary antibody to ERa or preimmune IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was incubated with the supernatants for 1 h at 4 8C. Antigen-antibody complexes were precipitated by incubation with protein A/G agarose (Santa Cruz Biotechnology) for 1 h at 4 8C. Immunoprecipitated protein complexes were washed thrice with 1 ml lysis buffer and separated by SDS-PAGE as described below. The blots were incubated with anti-SRC-1, CBP, and NCoR antibodies to determine interaction with ERa in cellular lysates and also stripped and incubated with anti-ERa antibody to determine the amount of immunoprecipitated protein in each lane. For western blots, 75 mg total cellular protein was separated by SDS-PAGE on 10% resolving gels under denaturing and reducing conditions. Separated proteins were electroblotted to PVDF membranes according to the manufacturer's recommendations (Roche Molecular Biochemicals) and the blots were incubated with antibodies to human ERa, SRC-1, p21, p27, extracellular signal regulated kinase 1 (ERK1), cyclin A, cyclin B, cyclin D1, cyclin E, cdk1, cdk2, cdk6, c-myc, and b-actin (Santa Cruz Biotechnology) for 16 h at 4 8C. After washing in Tris-buffered saline containing 0 . 1% Tween 20 (TBST, pH 7 . 4), blots were incubated for 30 min at room temperature with anti-IgG secondary antibody conjugated to horseradish peroxidase. Following extensive washing in TBST, bands were visualized by the enhanced chemiluminescence method (Roche Molecular Biochemicals) and quantitated using laser densitometry. Statistical analysis was performed by t-test.
Transient transfection and reporter gene analysis
Triplicate cultures of 50% confluent SCC25 cells were transiently transfected with 5 mg of the estrogen-responsive ERE-luc (estrogen response element fused to luciferase cDNA) or ERK1 promoter/reporter vectors (Chu et al. 2005) along with 2 mg SRC-1, CBP, NCoR, or blank expression plasmids using Lipofectamine according to the manufacturer's recommendations (Invitrogen). One microgram b-galactosidase expression plasmid was used to normalize for transfection efficiency. Cultures were treated with 100 nM E2, TAM, or vehicle for 24 h. Cells were harvested and the reporter gene activity determined using a commercially available kit (Tropix, Bedford, MA, USA). Luciferase activity was normalized to b-galactosidase levels for each sample.
Chromatin immunoprecipitation SCC25 clones were treated with 100 nM E2, TAM, or vehicle for up to 4 h. After washing in PBS, cells were fixed in 1% formaldehyde for 10 min at room temperature. The cells were washed in PBS and lysed in immunoprecipitation buffer containing protease inhibitors for 30 min at 4 8C, sheared and centrifuged at 10 000 g for 10 min and the supernatants were cleared with 2 mg sheared salmon sperm DNA, 20 ml preimmune serum, and 20 ml protein A/G sepharose beads for 2 h at 4 8C. Aliquots of the supernatant were used as input DNA for normalization and amplified with b-actin PCR primers (5 0 -ACAGGAAGTCCCTTGCCATC-3 0 and 5 0 -ACTGGTCTCAAGTCAGTGTACAGG-3 0 ). Immunoprecipitation using anti-SRC-1 or anti-CBP antibodies (Santa Cruz Biotechnology) was performed overnight at 4 8C. Preimmune IgG was used as the negative control antibody. The immunoprecipitates were washed extensively in immunoprecipitation buffer, resuspended in 10 mM Tris-HCl, 1 mM EDTA (TE, pH 8) and incubated at 65 8C for 6 h to reverse crosslinks. The supernatants were extracted with phenol/chloroform and ethanol precipitated. Following washing in 70% ethanol, pellets were dried and suspended in 50 ml TE. For PCR, 1 ml template was amplified in buffer containing 10 mM Tris-HCl (pH 8 . 3), 50 mM KCl, 2 . 5 mM MgCl 2 , 200 nM each dNTP, and 100 ng each primer (5 0 -CCACCACATAGAGAGCCTTTGG-3 0 and 5 0 -CACTCCTGCCGCCTCCCC-3 0 ) flanking the K390 to K10 region of the ERK1 promoter. The optimized cycle parameters were one cycle at 94 8C for 3 min followed by 25 cycles of 94 8C for 25 s, 55 8C for 60 s, 72 8C for 60 s, and one final cycle at 72 8C for 10 min. Amplified products were separated by agarose gel electrophoresis.
Results
To determine how estrogen receptor a (ERa) signaling regulates proliferation of cancer cell lines derived from stratified squamous epithelium, we treated human SCC lines with E2 or TAM for up to 6 days. All SCC lines expressed low levels of ERa as shown by immunoprecipitation (three representative lines shown in Fig. 1A ). ERa mRNA levels were 75-90% lower than those observed in the ERa positive human breast cancer cell line MCF7 ( Fig. 1B ; P!0 . 0001). The ERa expression in the ERa-negative breast cancer cell line MDA-MB-231 is shown for comparison. E2 treatment at concentrations up to 1000 nM had no effect on the proliferation of human SCC lines in these assays. We next tested the effects of TAM treatment at concentrations from 10 to 1000 nM; maximal growth inhibition was achieved using the 100 nM concentration. TAM, 100 nM, inhibited prolifer- effects of TAM when the two ligands were combined in culture, indicating that these effects were mediated through ERa. To determine how TAM regulated cell cycle progression of SCC lines, we performed BrdU incorporation analysis and analyzed cell cycle regulatory protein expression. As shown in Fig. 2A , TAM reduced the percentage of BrdU-positive cells in the SCC4, SCC9, and SCC25 lines from 13 to 7%, 14 to 7%, and 16 to 9% respectively (P!0 . 02). E2 had no effect on BrdU incorporation in treated cell lines compared with control cultures. TAM treatment induced expression of the cyclindependent kinase inhibitor p27
Kip1 by sixfold in SCC4 and SCC9 cells (Fig. 2B) . Expression of the G1/S phase cell cycle regulatory protein cyclin E was reduced by sevenfold in TAM-treated cells. Expression of the G1 cyclin-dependent kinase cdk6 also was inhibited by fivefold in TAM-treated SCC4 and SCC9 cells. We also examined expression of the estrogen target genes cyclin D1, c-myc, and p21
, but these protein levels were too low to be detected by western blot. These results indicate that, while TAM inhibited G1/S phase cell cycle progression of SCC lines, E2 had no effect on the proliferation of these cells.
We hypothesized that the lack of proliferative response to E2 and inhibitory effects of TAM may be due to differential recruitment of coactivator proteins to ERa. To test this hypothesis, we immunoprecipitated ERa from three E2 and TAM-treated human SCC lines to examine interaction with coactivator proteins. Representative results from SCC25 cells are shown in Fig. 3 . The E2 treatment dissociated the NCoR protein NCoR from ERa (Fig. 3A) . In contrast, complex formation between ERa and NCoR was increased threefold by TAM treatment compared with vehicle-treated control cultures. These results indicate that NCoR interaction with ERa was largely intact in human SCC lines. Similarly, the coactivator protein CBP was recruited to ERa in E2-treated cells. This interaction was not observed in TAM-treated cells. Given that SRC-1 can interact with CBP, we expected that SRC-1 would co-immunoprecipitate with ERa. However, we did not detect the presence of SRC-1 protein in the immunoprecipitated complexes from either E2 or TAMtreated cells. This lack of SRC-1 interaction with ERa transcriptional complexes made this coactivator a potential candidate for mediating E2 proliferative responses in human SCC lines. To determine if SRC-1 could enhance transcription from an E2 responsive promoter, we transiently transfected SRC-1, CBP, or NCoR with the ERE-luc reporter vector into E2 or TAM-treated SCC lines. Representative results from SCC25 cells are shown in Fig. 3B . SRC-1 induced the activity of the estrogenresponsive promoter by fourfold in vehicle-treated cells (P!0 . 01). This SRC-1-mediated transactivation was increased to sevenfold when transfected cells were treated with E2. However, TAM treatment repressed SRC-1 transactivation by 25% compared with vehicle-treated cells (P!0 . 05). CBP overexpression induced ERE-luc activity by threefold, although transactivation by this coactivator was less sensitive to E2 or TAM treatment (P!0 . 05). NCoR repressed the activity of the estrogen-responsive promoter by 50% (P!0 . 02), which was largely unaffected by E2 or TAM treatment, likely due to overexpression of this corepressor protein. These results indicate that SRC-1 is a key mediator of the transcriptional response to E2 in human SCC lines.
SRC-1 protein expression was not detected in SCC lines by western blot (Fig. 4A) . We created stable SRC-1 expressing clones in order to assess the effect of the coactivator on estrogen response in SCC lines. The expression of SRC-1 protein in stable clones is shown in Fig. 4A . To determine if SRC-1 protein could interact with ERa in these clones, we immunoprecipitated ERa from E2 and TAM-treated cultures. E2 treatment recruited SRC-1 and CBP to ERa while displacing NCoR (Fig. 4B) . Conversely, NCoR was strongly associated with ERa in TAM-treated cells. The SRC-1 interaction with ERa was undetectable in TAMtreated cells, and receptor association with CBP was reduced by twofold compared with vehicle-treated cultures. These results indicate that SRC-1 can form transcriptional protein complexes with CBP and ERa in SCC lines.
To determine the effect of E2 on proliferation of SRC-1 expressing clones, we treated SCC4 and SCC25 cells expressing SRC-1 protein or the neomycin resistance gene product with E2 for up to 6 days. As shown in Fig. 4C and D, SRC-1 expression produced E2 responsive increases in cellular proliferation in vitro. SCC4 clones expressing SRC-1 protein proliferated 60% faster than control clones when treated with E2 (P!0 . 01). Additionally, SCC25 cells expressing SRC-1 protein proliferated 25% faster than control clones when treated with E2 (P!0 . 05). TAM treatment inhibited proliferation of SRC-1 expressing clones similar to that observed in neomycin resistant cells, likely due to efficient recruitment of NCoR to ERa by TAM and SRC-1 displacement from the receptor in these clones. To determine how E2 regulated cell cycle progression in SRC-1 expressing clones, we examined G1/S phase progression and expression of cell cycle regulatory proteins by western blot. As shown in Fig. 4E , E2 treatment increased BrdU incorporation in SRC-1 expressing clones (13) (14) (15) (16) (17) (18) (19) in SCC25; P!0 . 05 and 0 . 04 respectively). E2 treatment had no effect on neomycin resistant clones. S phase progression was inhibited to a similar degree by TAM treatment in both neomycin resistant and SRC-1 expressing clones. Expression of the mitogen-activated protein kinase ERK1 was induced threefold in SRC-1 expressing clones by E2 treatment (Fig. 4F) . Expression of the S and G2 phase cyclins A and B was two-to three-fold higher in SRC-1 expressing clones, but was not affected by E2 treatment. Expression of the S phase cyclin-dependent kinase cdk2 was induced eightfold in SRC-1 expressing clones by E2 treatment, and the G2 phase kinase cdk1 was increased twofold. The E2 treatment had little effect on cell cycle regulatory protein expression in control clones. These results indicate that SRC-1 induces E2-mediated proliferation in human SCC lines.
To determine if transfected SRC-1 formed transcriptional complexes on chromatin, we performed ChIP on the proximal ERK1 promoter in E2 and TAM-treated SCC lines. The ERK1 expression was increased by E2 treatment in SRC-1 expressing clones (Fig. 4F) . As shown in Fig. 4G , SRC-1 and CBP bound to the proximal ERK1 promoter in clones expressing SRC-1 but not in control cells. SRC-1 interaction with the proximal ERK1 promoter was increased by fivefold when SRC-1 clones were treated with E2. CBP interaction with the proximal ERK1 promoter increased threefold in E2-treated clones. TAM treatment reduced SRC-1 and CBP binding to the proximal ERK1 promoter. SRC-1 and CBP induced ERK1 promoter activity by threefold in reporter gene assays ( Fig. 4H ; P!0 . 04). E2 treatment increased induction of the ERK1 promoter to sevenfold for SRC-1 (P!0 . 03) and fourfold for CBP (P! 0 . 02). TAM treatment inhibited ERK1 promoter activation by SRC-1 and CBP (twofold induction; P!0 . 05). These results indicate that SRC-1 can form E2 responsive transcriptional complexes on the promoters of target genes in human SCC lines.
Discussion
The results of the present study have potentially important clinical ramifications in treatment of cancers from nonreproductive tissues. We showed that TAM inhibited proliferation of human SCC lines by inhibiting G1 to S phase progression. This inhibition correlated with the upregulation of p27
Kip1 expression and the downregulation of cyclin E and cdk6 protein levels. A similar mechanism of TAM-mediated growth inhibition was shown in human pancreatic cancer cell lines in which the anti-estrogen induced p21 WAF1/Cip1 expression (Robinson et al. 1998 ). TAM upregulated p21 WAF1/Cip1 and p27 Kip1 in human breast cancer cells and inhibited cyclin E-cdk2 kinase activity (Cariou et al. 2000) . The p27 overexpression induced cell cycle arrest in TAM-treated breast cancer cell lines (Carroll et al. 2003) . Initiation of cell cycle progression in these cells required dissociation of NCoR from ERa. We have demonstrated that TAM promoted complex formation between NCoR and ERa in agreement with the previous studies (Shang et al. 2000) . NCoR has been shown to interact with helices 3 and 5 of the receptor ligand-binding domain in a TAM-dependent manner (Yamamoto et al. 2001) . A tumorderived ERa mutant containing an amino acid substitution in helix 3 showed reduced interaction with NCoR and high (vector, SRC cl1, SRC cl2) was determined by western blot using anti-SRC-1 antibody. The blots were stripped and incubated with anti-b-actin antibody to determine relative amounts of protein in each lane. These experiments were performed thrice using different cell lines with similar results. Representative blots are shown. (B) Differential recruitment of NCoR and SRC-1 to ERa in response to estradiol and tamoxifen in SRC-1 stable clones. SCC25 clones were treated with vehicle, 100 nM estradiol (E2), or 100 nM tamoxifen (TAM) for 4 h as described in Materials and Methods. ERa was immunoprecipitated from cell lysates (IP ER) using anti-ERa antibody. The immunoprecipitated proteins were blotted and incubated with anti-NCoR, SRC-1, or CBP antibodies to determine complex formation and the blots were also incubated with anti-ERa antibody to determine relative amounts of the immunoprecipitated protein in each lane. These experiments were performed thrice using different clones with similar results. Representative blots are shown. (C and D) SRC-1 expression restores the proliferative response to estradiol in human SCC clones. SCC4 and SCC25 SRC-1 and neomycin resistant (neo) clones were treated with vehicle, 100 nM estradiol (CE2), or 100 nM tamoxifen (CTAM) for 6 days. At 2-day intervals, triplicate cultures were counted using a hemacytometer. These experiments were performed thrice with similar results. Error bars indicate S.E.M. (E) SRC-1 expression increases S phase progression in E2-treated SCC clones. Neomycin resistant (neo) and SRC-1 expressing SCC4 and SCC25 clones were treated with 100 nM estradiol (E2) or tamoxifen (TAM) for 16 h before being labeled with BrdU as described in Materials and Methods. BrdU-positive cells were identified using immunofluorescence microscopy and reported as the percentage of total cells counted. These experiments were performed thrice with similar results. Error bars indicate S.E.M. (F) Estradiol treatment induces cell cycle regulatory protein expression in SRC-1 expressing clones. SRC-1 and vector expressing clones were treated with 100 nM estradiol (CE2) or vehicle for 24 h prior to protein extraction and western blotting using antibodies indicated at left. The blots were stripped and incubated with anti-b-actin antibody to determine relative amounts of protein in each lane. These experiments were performed thrice using different clones with similar results. Representative blots are shown. (G) SRC-1 and CBP are bound to the ERK1 promoter in estradiol-treated SCC clones. Chromatin immunoprecipitation using SRC-1 and CBP antibodies was performed as described in Materials and Methods using lysates from vehicle, estradiol, and tamoxifen-treated SRC-1 and vector expressing clones. Input genomic DNA was amplified prior to immunoprecipitation to determine relative amounts of DNA in each sample. These experiments were performed thrice using lysates from different clones with similar results. Representative gels are shown. (H) SRC-1 and CBP transactivate the ERK1 promoter. The ERK1 promoter was transiently cotransfected with SRC-1 or CBP expression vectors into triplicate cultures of SCC25 cells, which were treated with 100 nM estradiol (E2), tamoxifen (TAM), or vehicle for 24 h prior to harvesting for reporter gene assays. Luciferase activity was measured as relative light units normalized to the activity of a control reporter construct as described in Materials and Methods. These experiments were performed thrice with similar results. Error bars represent S.E.M.
TAM-induced transcriptional activation. These preclinical studies suggest that TAM may be a useful clinical adjunct in cancers from non-reproductive tissues, perhaps in combination with standard chemotherapy agents (Tavassoli et al. 2002) .
One of the key results of this study was the dependence on SRC-1 for E2-mediated proliferative response in cancer cells from non-reproductive tissues. Stratified squamous epithelia such as skin are E2 responsive (Kanda & Watanabe 2004) . Clinically, decreased estrogen levels associated with menopause correlate with epidermal thinning, and estrogen containing skin creams have been shown to increase epidermal thickness (Fuchs et al. 2003 , Hall & Phillips 2005 . The E2 induces proliferation of neonatal keratinocytes in vitro, which express both ERa and ERb (Verdier-Sevrain et al. 2004) . ERb was expressed by many cell types in skin from the human scalp, while ERa was localized to the dermal papilla and sebocytes (Thornton et al. 2003) . However, a study using ERa null mutant mice indicated that only ERa mediated keratinocyte proliferation in vivo (Moverare et al. 2002) . Little is known about SRC-1 expression in normal epidermal keratinocytes or ERa expression in SCCs, but the lack of E2 response in these cancers suggests that SRC-1 expression may be lost during carcinogenesis. One previous report demonstrated that TAM induced programmed cell death in SCC lines (Hoffmann et al. 2002) , but only at high doses (up to 10 mM). TAM has been shown to have opposing effects on different tissues such as breast and uterus (Shang & Brown 2002) . The estrogenic effect of TAM in the uterus was shown to require high levels of SRC-1 expression. In mouse epidermis, TAM inhibits u.v.-induced DNA damage (Wei et al. 1998) and is used in clinical treatment of dendritic cellmediated allergic dermatitis (Yotsumoto et al. 2003) . These studies suggest that as a potential chemotherapeutic agent, TAM would be more effective against cancer cells with low levels of coactivator expression.
Our results demonstrated that ERK1 expression is induced by SRC-1. This induction was mediated at the transcriptional level through direct interaction of SRC-1 and CBP with the proximal ERK1 promoter. These interactions were enhanced by E2 treatment and inhibited by cellular exposure to TAM. The proximal ERK1 promoter contains a number of transcription factor binding sites including those for AP-1 (Chu et al. 2005) . The SRC-1 has been shown to bind directly to fos and jun subunits . Coexpression of CBP/p300 enhanced SRC-1-dependent transactivation, which was corroborated by our results using the ERK1 promoter. SRC-1 also has been shown to interact with serum response factor and enhances transactivation from this responsive element . Coexpression of CBP/p300 also enhanced transactivation from serum response elements. Alternatively, ERa also has been shown to interact directly with and transactivate AP-1 subunits in vitro (Cheung et al. 2005) . These results suggest the existence of multiple mechanisms by which E2 can activate target gene expression through coactivators.
In summary, we show that SRC-1 was a key molecular determinant of estrogen-mediated proliferation in human SCC lines. TAM treatment inhibited cell cycle progression and proliferation of human cancer lines derived from stratified squamous epithelium. SRC-1 expression was not detected in these SCC lines; however, transient transfection of SRC-1, CBP, or both coactivators enhanced transactivation of an estrogen-responsive promoter in cancer cells treated with E2 or TAM. SRC-1 expression restored the E2-mediated proliferative response to human SCC lines. This increased proliferation correlated with increased ERK1 expression. SRC-1 and CBP were recruited to the proximal ERK1 promoter region in E2 but not TAM-treated cells. Future studies will focus on specific interactions of SRC-1 and CBP with transcription factor response elements in the proximal ERK1 promoter and examine the role of ERb in SCC proliferation.
